Cargando…
Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
Autores principales: | Davila, Eduardo, Melchiori, Luca, Wong, Ryan, Binder-Scholl, Gwendolyn, Amado, Rafael, Jakobsen, Bent, Rapoport, Aaron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649278/ http://dx.doi.org/10.1186/2051-1426-3-S2-P295 |
Ejemplares similares
-
NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015) -
Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
por: Rapoport, Aaron P, et al.
Publicado: (2013) -
Optimizing engineered TCR T cell therapy for synovial sarcoma
por: D'Angelo, Sandra, et al.
Publicado: (2015) -
TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
por: Alsalloum, Alaa, et al.
Publicado: (2023) -
Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)